... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2022 Warfarin Mistletoe Drug interactions Nab-paclitaxel Pancreatic cancer Mistletoe, Viscum album , is a medicinal plant with antispasmodic, hypoglycemic...

...Hyun Ae Jung; Bo Ram Han; Ho Young Kim; Hyo Jung Kim; Dae Young Zang; Joo Young Jung Background and Aims: Although pancreatic cancers are common in older age-groups, the prognosis remains poor due to limited studies on treatment approaches and outcomes in a given population. We aimed to examine...

...Kotone Hayuka; Hiroyuki Okuyama; Akitsu Murakami; Yoshihiro Okita; Takamasa Nishiuchi; Keiichi Okano; Yasuyuki Suzuki; Akihito Tsuji Introduction: Patients with advanced pancreatic cancer have a poor prognosis. FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) have been established...

..., instructions or products referred to in the content or advertisements. Pancreatic cancer Neuroendocrine tumors Everolimus Pancreatic neuroendocrine tumors (pNET), a heterogeneous group of neoplasms of the pancreas, account for approximately 1% of all cases of pancreatic cancer by incidence...

...Zuojia Liu; Dan Li; Lijun Yu; Fenglan Niu Background: Gallic acid (GA) is a plant phenol isolated from water caltrop which is reported to have anti-inflammatory and anti-cancer effects. In this study, the antiproliferative effect of GA on human pancreatic cancer cell lines CFPAC-1 and MiaPaCa-2...

...Tao Yin; Hongji Wei; Zhenwei Leng; Zhiyong Yang; Shanmiao Gou; Heshui Wu; Gang Zhao; Xiaoqing Hu; Chunyou Wang Background/Aims: The polycomb protein Bmi-1 plays oncogenic roles in various cancers. Here we aimed to investigate the contribution of Bmi-1 on the malignant behaviors of pancreatic cancer...

...Stefano Cereda; Michele Reni; Alessia Rognone; Clara Fugazza; Michele Ghidini; Domenica Ceraulo; Matteo Brioschi; Roberto Nicoletti; Eugenio Villa Background: At the time of upfront treatment failure, over half of the patients with advanced pancreatic cancer are candidates for further treatment...

... in gemcitabine (GEM)-resistant pancreatic cancer cells and that it suppressed the cytotoxic effect of GEM on the cells. This report describes the benefits of a treatment strategy combining the HSP inhibitor KNK437 with GEM for GEM-resistant pancreatic cancer cells. Methods: We used 2 human pancreatic cancer cell...

...Mitsugi Shimoda; Masato Katoh; Junji Kita; Tokihiko Sawada; Keiichi Kubota Background: We analyzed the outcome of patients with advanced unresectable pancreatic cancer treated in our department from 2001 to 2008. Methods: Of the 83 patients included in this study, 50 patients received single-agent...

...Simona Ricciardi; Valentina Mey; Sara Nannizzi; Giuseppe Pasqualetti; Francesco Crea; Mario Del Tacca; Romano Danesi Background: Current treatments have a modest impact on survival of pancreatic cancer patients and this study investigates the interaction between sorafenib and gemcitabine...

.../ml), verapamil and hyperthermia had a synergistic growth-inhibitory effect and caused a significant decrease in cell count by 81.4% in comparison to the control. The modalities analyzed in this study require further investigation and have potential for clinical applicability to pancreatic cancer...

...Hawk Kim; Jae-Hoo Park; Su Jin Shin; Mee-Ja Kim; Sung-Jo Bang; Neung Hwa Park; Yang Won Nah; Chang Woo Nam; Kwang Ro Joo; Young Joo Min The standard beneficial chemotherapy proven for patients with advanced pancreatic cancer is a regimen containing gemcitabine. In the pregemcitabine era, 5...

... to in the content or advertisements. Multitargeted antifolate Pemetrexed Pancreatic cancer Gastric cancer Colorectal cancer Review Chemotherapy 2008;54:1 8 DOI: 10.1159/000112311 Received: June 16, 2006 Accepted after revision: January 13, 2007 Published online: December 7, 2007 The Potential Role...

.... Pancreatic cancer Complete remission G-FLIP Gemcitabine Cetuximab Experimental Chemotherapy Chemotherapy 2007;53:356 359 DOI: 10.1159/000107692 Received: February 7, 2006 Accepted after revision: July 24, 2006 Published online: September 3, 2007 Complete Remission of a Metastatic Pancreatic Carcinoma...

...Satoshi Tanno; Yasuhiro Nakano; Manabu Osanai; Kazuya Koizumi; Tsutomu Izawa; Atsuya Habiro; Yusuke Mizukami; Nobuyuki Yanagawa; Tsuneshi Fujii; Toshikatsu Okumura; Yutaka Kohgo Background: Gemcitabine is widely accepted as the first-line agent for advanced pancreatic cancer. The antitumor cell...

...Isao Kurosaki; Katsuyoshi Hatakeyama Background: The effects of gemcitabine on postoperative adjuvant chemotherapy were evaluated in patients with stage IV pancreatic cancer. The results were compared with those of our historical control patients treated with surgery alone. Patients and Methods...

...Lawrence Rosenberg The incidence of adenocarcinoma of the pancreas has risen steadily over the past 4 decades. Since pancreatic cancer is diagnosed at an advanced stage, and because of the lack of effective therapies the prognosis of such patients is extremely poor. Despite advances in our...